Biotech Venture Funding Tracker 2026
Private financings — Company, date, round, investors, therapeutic area, and a one-line
"what they do."
Last updated:
15 Feb 2026
Unlock the full 2026 VC tracker + get deal alerts
Subscribe (free) to access the full table and get new financings as they land — in
~5 mins/day, read by 2,000+ VC, BD&L, and public biotech investors.
No spam. Unsubscribe anytime.
February 2026
Immunic
Private Placement
Date:
13-Feb-2026
|
Size:
Up to US$400M (US$200M upfront)
|
Therapeutic area:
Neurology / neuroimmunology (multiple sclerosis) + GI
Investors:
Led by BVF Partners L.P.; participants include Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other institutional investors
What they do:
Late-stage biotech developing oral therapies for neurologic and gastrointestinal diseases. Financing includes pre-funded warrants for upfront gross proceeds of US$200M plus warrants for up to an additional US$200M; proceeds intended to fund Phase 3 ENSURE trials in relapsing MS, initiate a Phase 3 trial in primary progressive MS, and support transition toward a commercial organization.
ILiAD Biotechnologies
Series B
Date:
09-Feb-2026
|
Size:
US$115M
|
Therapeutic area:
Infectious disease / vaccines (pertussis)
Investors:
Led by RA Capital Management; participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts; existing investors include a multi-national pharmaceutical company and AI Life Sciences
What they do:
Advanced clinical-stage biotech focused on prevention/treatment of Bordetella pertussis. Lead candidate BPZE1 is a live attenuated intranasal pertussis vaccine designed to induce systemic + mucosal immunity; proceeds to support Phase 3 development with a pivotal human challenge trial expected to begin in 2026.
QuantX Biosciences
Series B
Date:
09-Feb-2026
|
Size:
US$85M
|
Therapeutic area:
Immunology & inflammation (oral small molecules)
Investors:
Co-led by Lilly Asia Ventures (LAV) and Sanofi Ventures; additional investors included Hongshan; plus existing investors
What they do:
Computationally driven drug discovery/development company using advanced modeling + high-performance computing to design and optimize oral small-molecule therapeutics. Proceeds to support clinical development of a best-in-class oral STAT6 inhibitor and an oral IL-17 inhibitor, plus continued discovery for oral I&I therapies.
Aerska
Series A
Date:
09-Feb-2026
|
Size:
US$39M
|
Therapeutic area:
CNS / neurology (RNA medicines; RNAi delivery)
Investors:
Led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors
What they do:
Biotech developing RNA medicines for CNS diseases using proprietary “brain shuttle” technology to improve delivery of RNAi therapeutics across the blood-brain barrier. Proceeds support continued development of its antibody-oligo conjugate (AOC) platform as it progresses toward the clinic.
Galux
Series B
Date:
09-Feb-2026
|
Size:
US$29M
|
Therapeutic area:
AI-driven protein therapeutics / antibody design platform
Investors:
Existing investors InterVest, DAYLI Partners, and PATHWAY Investment; new investors include Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities
What they do:
South Korea-based biotech building an AI-driven protein design platform focused on de novo antibody design. Proceeds support platform R&D, pipeline development, and global expansion (including next-gen AI incorporating functional activity + developability).
Pandorum Technologies
Series B
Date:
07-Feb-2026
|
Size:
US$18M
|
Therapeutic area:
Regenerative medicine (exosome-based; ophthalmology-first)
Investors:
Led by Protons Corporate; participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, Burman Family, and others
What they do:
Biotech developing disease-modifying, tunable, exosome-based regenerative therapies. Proceeds to advance clinical development (including Kuragenx) while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East.
Angitia Biopharmaceuticals
Series D
Date:
05-Feb-2026
|
Size:
US$130M
|
Therapeutic area:
Musculoskeletal / Bone (osteoporosis, OI, spinal fusion)
Investors:
Co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners; new investors include Ascenta Capital, funds/accounts managed by BlackRock, BVF Partners, Logos Capital, RA Capital Management, Wellington Management; existing investors include Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital, Yonghua Capital
What they do:
Clinical-stage biotech developing biologics aimed at improving musculoskeletal health; proceeds support clinical development of AGA2118, AGA2115, AGA111 and broader pipeline.
Third Arc Bio
Series A Extension
Date:
04-Feb-2026
|
Size:
US$52M
|
Therapeutic area:
Oncology + Immunology/Inflammation (multispecific antibodies)
Investors:
Led by Andreessen Horowitz (a16z) with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners, funds managed by abrdn, accounts advised by T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, Galapagos, AbbVie Ventures, Alderline Group
What they do:
Clinical-stage biotech developing multifunctional/multispecific antibodies across oncology and I&I; lead program ARC101 is a bispecific T-cell engager (CLDN6) in Phase 1; proceeds accelerate I&I portfolio and advance additional oncology programs into clinic.
AccurEdit Therapeutics
Series A
Date:
04-Feb-2026
|
Size:
US$75M
|
Therapeutic area:
Gene editing / Genetic medicine (in vivo)
Investors:
Not disclosed in publicly available reporting (coverage notes the round size/date; investor list not provided)
What they do:
Suzhou-based gene editing company developing in vivo CRISPR medicines; lead clinical programs include ART001 (ATTR) and ART002 (PCSK9) in human studies, with broader expansion into additional in vivo gene editing applications.
Phylo
Seed
Date:
03-Feb-2026
|
Size:
US$13.5M
|
Therapeutic area:
Research tools / AI-native biology (agentic lab environment)
Investors:
Co-led by Andreessen Horowitz (a16z) and Menlo Ventures’ Anthology Fund (with Anthropic); participation from Zetta, Conviction, SV Angel, and others
What they do:
Applied AI research lab launching “Biomni Lab,” an integrated biology environment that lets scientists plan, execute, and collaborate on complex research tasks using agentic AI + domain tools in a unified workspace.
Biorce
Series A
Date:
02-Feb-2026
|
Size:
US$52.5M
|
Therapeutic area:
Clinical development / Trial ops (AI platform)
Investors:
DST Global Partners; existing investors Norrsken VC and YZR Capital (increased); Mustard Seed Maze; plus angel investors (incl. Arthur Mensch, Nik Storonsky, Paulo Rosado, Albert Nieto) (and some reports also cite Endeavor Catalyst participation)
What they do:
Builds “Aika,” an AI-native platform to improve clinical trial design and execution—aiming to reduce protocol design time and protocol amendments (and associated delays/costs) across therapeutic areas.
January 2026
Breakthru Medicine
Series A
Date:
29-Jan-2026
|
Size:
US$60M
|
Therapeutic area:
Oncology (multi-modality platform)
Investors:
Not disclosed (press release notes board/investors including Dave Morehead; Fred
Eshelman (Eshelman Ventures); Mark Gergen)
What they do:
Oncology company developing "disruptive therapeutic modalities" for solid tumors;
platform spans small molecules, next-gen ADC payloads, and molecular glues (details of
specific programs not publicly disclosed at announcement).
Tenpoint Therapeutics
Series B + Credit Facility
Date:
28-Jan-2026
|
Size:
US$235M total (US$85M Series B + US$150M term loan)
|
Therapeutic area:
Ophthalmology (presbyopia)
Investors:
Series B led by Janus Henderson, EQT Nexus, Hillhouse, British Business Bank; existing
EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners
USA, AdBio, Wille; term loan facility from Hercules Capital
What they do:
Commercial biotech focused on rejuvenating vision in the aging eye; financing supports
commercialization/launch of YUVEZZI (carbachol + brimonidine) for presbyopia
(once-daily dual-agent eye drop).
Sensorion
Public Financing / Reserved Offering
Date:
28-Jan-2026
|
Size:
€60M (incl. €20M strategic)
|
Therapeutic area:
Genetic medicine (hearing loss)
Investors:
Sanofi (€20M strategic); existing Redmile Group, Artal (advised by Invus), Sofinnova
Partners; other investors incl. Cormorant Asset Management, Coastlands Capital, Sphera
Healthcare
What they do:
Clinical-stage biotech developing genetic medicines to restore/treat/prevent hearing
loss; proceeds support SENS-601 (GJB2 gene therapy) advancement toward clinic and
continued development of SENS-501.
TRex Bio
Financing
Date:
27-Jan-2026
|
Size:
US$50M (oversubscribed)
|
Therapeutic area:
Immunology / inflammation (tissue Treg biology)
Investors:
New Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors;
existing Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli
Lilly and Company, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris
Partners, SV Health Investors
What they do:
Clinical-stage biotech developing precision immunoregulatory medicines based on tissue
Treg biology; proceeds support continued development of TRB-061 (TNFR2 agonist) in
atopic dermatitis and advancement of preclinical programs TRB-071/TRB-081 toward the
clinic.
CORXEL
Series D
Date:
22-Jan-2026
|
Size:
US$287M (up to)
|
Therapeutic area:
Cardiometabolic (obesity / T2D)
Investors:
New SR One, TCG Crossover (TCGX), RA Capital, HBM Healthcare Investments, SymBiosis,
Adage, Invus, SilverArc (+ others); existing RTW Investments, Hengdian Group Capital
What they do:
Clinical-stage cardiometabolic biotech advancing CX11, an oral small-molecule GLP-1
receptor agonist; proceeds support ongoing U.S. Phase 2 obesity study, planned global
Phase 2 in T2D, and Phase 3 preparations (plus other cardio-metabolic programs).
Mendra
Series A
Date:
22-Jan-2026
|
Size:
US$82M
|
Therapeutic area:
Rare disease (asset acquisition + AI-enabled development)
Investors:
Co-led OrbiMed, 8VC, 5AM Ventures; participation Lux Capital, Wing VC
What they do:
Builds a portfolio by acquiring underdeveloped rare disease assets and using AI across
development + commercialization (e.g., patient identification, trial enrollment, global
access) to shorten timelines for underserved patient populations.